RIGHT ISSUE OF UNITS - SUBSCRIPTION PERIOD 1-15 JULY
Sign up directly with the issuing agent, Nordic Issuing.
Find more information about the rights issue here
On the business / CEO’s message:
This is a brief introduction on how to sign for units without unit rights in the ongoing rights issue with PILA PHARMA, concluding on July 15, 2025 at 23:59 CET.
If you are an investor without unit rights, this video will go through the steps of how to sign for units through our issuing agent Nordic Issuing.
Find the link to the video (In English) here
SIT-DOWN INTERVIEW WITH FINWIRE TALKING FUNDRAISING AND BET ON OBESITY [July 04, 2025]
CEO Gustav H. Gram begins by introducing the PILA PHARMA ‘oral solution for obesity, a TRPV1-antagonist, a very different target to other drugs in development for obesity and diabetes. He emphasizes how the obesity market has grown tremendously and is increasingly looking to fragment and how oral solutions will be key to address the huge volume of people living with overweight globally.
He also talks about their ongoing rights issue of units, where the company wish to fund dedicated obesity studies in rats and humans living with overweight. With the issue quite remarkably covered by pre-commitments to 99,87%, and why PILA PHARMA may present an attractive opportunity for investors in a market segment with estimates of more than 1 billion people living with obesity and value estimates of more than $100 billion annually by 2030.
Find the link to the video (In English) here
INTERVIEW ON RIGHTS ISSUE AND BET ON OBESITY WITH DIREKT STUDIOS [July 04, 2025]
PILA PHARMA’s CEO Gustav H. Gram discusses the ongoing rights issue together with Mathias Vahlne from Swedish financial media outlet, Direkt Studios, an issue which is which is covered by existing investors and guarantor pre-commitments to 99,87%.
PILA PHARMA wishes to use the proceeds to fund a venture into pure obesity studies with emphasis on achieving a comprehensive and meaningful data package that can facilitate a partnership. The Company’s overall aspirations remain to develop a new oral drug for obesity and diabetes treatment based on TRPV1 inhibition.
Find the link to the video (In English) here
Ongoing rights issue and bet on obesity with investment podcast 10x [July 3, 2025]
CEO Gustav H. Gram shares exciting updates on the company’s rights issue where the share offering, which is already 99% secured, and the proceeds will fuel a new venture in obesity with their promising pill treatment.
Find the link to the video (In English) here
“Der er noget helt usædvanligt ved den her kapitalrejsning, og det er jo at den er forhåndsgaranteret til 100%” – Helge Larsen
PILA PHARMA og adm. direktør Gustav Hanghøj Gram har været tilbage hos ProInvestor og snakke om den store tilslutning og opbakning til vores kapitalrejsning der skal finansiere nye dedikerede fedme studier med PILA PHARMA’s tablet baseret på TRPV1 hæmning – en helt ny og anderledes fremgangsmåde!
Find the link to the video (In Danish) here
Pila Pharma visited Direkt Studios’ investment channel [June 16, 2025]
CEO Gustav H. Gram participated in person with Eric Lindeen from Swedish investment media outlet, Nyhetsbyrån Direkt Studios, briefly presenting PILA PHARMA and its differentiated approach to develop a new oral drug for obesity and diabetes treatment.
Find the link to the video (In English) here
Pila Pharma participated in investment podcast 10x [June 11, 2025]
CEO Gustav H. Gram participated in person with Joakim Båge from Swedish investment focused podcast, 10X, discussing both PILA PHARMA and its aspirations to develop a new oral drug for obesity and diabetes treatment.
Find the link to the video (In English) here
On the mechanism / Founders word:
Fedmemarkedet handler primært om glp1, senere er amylin blevet kendt, men det dansk-svenske biotekselskab Pila Pharma, grundlagt af Dorte X. Gram med rødder i Novo Nordisk, udvikler en oral behandling mod type 2-diabetes og fedme baseret på en såkaldt chili-receptor. Hør mere i denne video, hvor Helge Larsen har besøg af Dorte X. Gram.
Find the link to the video (In Danish) here
Obesity and diabetes are serious global health challenges.
In this interview with SVT (Swedish national public television broadcaster), Dorte shares her unique approach to tackling these issues—with the help of chili.
Watch and read the full article here to learn more about her vision and the science behind it (in Swedish).
We were incredibly honoured that the American Diabetes Association(ADA) featured PILA PHARMA AB in the Thought Leadership Film Series, a part of ADA’s 81st Scientific Sessions program in June 2021, starting today.
In the invitation letter, it was written: We are interested in profiling Pila’s pioneering research and development in the science surrounding TPRV1 inhibition, and how regulation of this mechanism has tremendous potential to be exploited for the treatment of diabetes.
Thank you so much to our scientific advisors Mark Evans and Jens Juul Holst for helping our previous CEO explain!
Watch the video (in English) here
